samedan logo
 
 
spacer
home > ebr > autumn 2002 > over the counter and through the woods: china's otc market in transition
PUBLICATIONS
European Biopharmaceutical Review

Over the Counter and Through the Woods: China's OTC Market in Transition

Winters in Shanghai can be particularly tough - cold grey days marked with heavy wind and rain. In a crowded city of 16 million, there are likely to be lots of colds and flu, and much like anywhere these sufferers will want fast and effective relief. Unless symptoms are severe, most Chinese will look to prescription-free OTC drugs purchased from a retail pharmacy, to ease their pain. This article looks at factors which signal growth in this sector, current obstacles and barriers which might preclude foreign participation and what changes are afoot to allow for a more open and competitive market.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ben Goodger, Head of the Asia Commercial Intellectual Property Group at Rouse & Co, Shanghai

Ben Goodger is an Executive of Rouse & Co International, specialists in intellectual property management and protection worldwide. Ben won an Open Exhibition to Keble College in 1981 and completed his Articles with Frere Cholmeley Bischoff. After qualification, he joined the city law firm of Denton Hall.
In 1993 he joined Dallas Brett and was made a Partner in 1996, before moving to Rouse & Co/Willoughby & Partners in 1997. His practice can broadly be split into three main areas: computers and Internet related law, 'hi-tech' (biotechnology, technology transfer, patents) and trademark protection/brand management. He re-located to Rouse & Co's Shanghai office in August 2002 to head up the firm's Asia Commercial Intellectual Property Group.

spacer
Ben Goodger
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

BioPh Europe

5-7 October 2010, Paris, France

All companies and organisations dealing with the research and development of new treatment methods made through biotechnological processes or which are derived from or use live organisms will benefit from the mix of exhibition, seminars and 121 partnering meetings at BioPh. BioPh Europe 2010 at Paris Nord Villepinte will offer you unrivalled networking and commercial opportunities in the world of drug research and manufacturing. 
More info >>

 
News and Press Releases

Glycotope GMBH

Berlin, Germany – August 4, 2010 Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX (GT-MAB 5.2-GEX) for the treatment of various solid cancers.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement